Bendamustine, Rituxan and Ara-C for mantle cell lymphoma – pro
An attemtp to improve upn the bendamusitne rituximab regimen led toa d evelopment of bendamusitne rituximab cytarabien regimen. A phase II study by Visco et al showed that the regimen was well tolerated and effective and that it could also be used as induction for stem cell collections. This combination elicited durable responses with a low incidence of severe or life-threatening adverse events but with significant transient myelosuppression. However, it remains a singellstudy, albeit confirmed by another small retroactive review by  Branca et al.
Antonio Branca, Ilaria Gianesello, Luca Brugnaro, Tamara Berno, Silvia Imbergamo, Federica Lessi, Kety Sammartin, Fabrizio Vianello, Fausto Adami, Gianni Binotto, Carmela Gurrieri, Livio Trentin, Carlo Visco, Renato Zambello, Francesco Piazza and Gianpietro Semenzato, Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience. Blood 2015 126:2710;
Carlo Visco, Silvia Finotto, Renato Zambello, Rossella Paolini, Andrea Menin, Roberta Zanotti, Francesco Zaja,Gianpietro Semenzato, Giovanni Pizzolo, Emanuele S.G. D’Amore, and Francesco Rodeghiero, Combination of Rituximab, Bendamustine, andCytarabine for Patients With Mantle-Cell Non-HodgkinLymphoma Ineligible for Intensive Regimens orAutologous Transplantation. J Clin Oncol 31:1442-1449. 2013